BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38316746)

  • 21. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
    Mill CP; Fiskus W; DiNardo CD; Qian Y; Raina K; Rajapakshe K; Perera D; Coarfa C; Kadia TM; Khoury JD; Saenz DT; Saenz DN; Illendula A; Takahashi K; Kornblau SM; Green MR; Futreal AP; Bushweller JH; Crews CM; Bhalla KN
    Blood; 2019 Jul; 134(1):59-73. PubMed ID: 31023702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
    Watanabe-Okochi N; Kitaura J; Ono R; Harada H; Harada Y; Komeno Y; Nakajima H; Nosaka T; Inaba T; Kitamura T
    Blood; 2008 Apr; 111(8):4297-308. PubMed ID: 18192504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unrelated hematopoietic stem cell transplantation for familial platelet disorder/acute myeloid leukemia with germline RUNX1 mutations.
    Toratani K; Watanabe M; Kanda J; Oka T; Hyuga M; Arai Y; Iwasaki M; Sakurada M; Nannya Y; Ogawa S; Yamada T; Takaori-Kondo A
    Int J Hematol; 2023 Sep; 118(3):400-405. PubMed ID: 36897502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone Marrow Morphology Associated With Germline
    Chisholm KM; Denton C; Keel S; Geddis AE; Xu M; Appel BE; Cantor AB; Fleming MD; Shimamura A
    Pediatr Dev Pathol; 2019; 22(4):315-328. PubMed ID: 30600763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome.
    Jongmans MC; Kuiper RP; Carmichael CL; Wilkins EJ; Dors N; Carmagnac A; Schouten-van Meeteren AY; Li X; Stankovic M; Kamping E; Bengtsson H; Schoenmakers EF; van Kessel AG; Hoogerbrugge PM; Hahn CN; Brons PP; Scott HS; Hoogerbrugge N
    Leukemia; 2010 Jan; 24(1):242-6. PubMed ID: 19946261
    [No Abstract]   [Full Text] [Related]  

  • 26. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML).
    Owen C
    Leuk Res; 2010 Feb; 34(2):141-2. PubMed ID: 19695705
    [No Abstract]   [Full Text] [Related]  

  • 28. RUNX1 haploinsufficiency results in granulocyte colony-stimulating factor hypersensitivity.
    Chin DW; Sakurai M; Nah GS; Du L; Jacob B; Yokomizo T; Matsumura T; Suda T; Huang G; Fu XY; Ito Y; Nakajima H; Osato M
    Blood Cancer J; 2016 Jan; 6(1):e379. PubMed ID: 26745853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies.
    Minelli A; Maserati E; Rossi G; Bernardo ME; De Stefano P; Cecchini MP; Valli R; Albano V; Pierani P; Leszl A; Sainati L; Lo Curto F; Danesino C; Locatelli F; Pasquali F
    Genes Chromosomes Cancer; 2004 Jul; 40(3):165-71. PubMed ID: 15138996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation.
    Krutein MC; Hart MR; Anderson DJ; Jeffery J; Kotini AG; Dai J; Chien S; DelPriore M; Borst S; Maguire JA; French DL; Gadue P; Papapetrou EP; Keel SB; Becker PS; Horwitz MS
    Blood Adv; 2021 Feb; 5(3):687-699. PubMed ID: 33560381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrative analysis of RUNX1 downstream pathways and target genes.
    Michaud J; Simpson KM; Escher R; Buchet-Poyau K; Beissbarth T; Carmichael C; Ritchie ME; Schütz F; Cannon P; Liu M; Shen X; Ito Y; Raskind WH; Horwitz MS; Osato M; Turner DR; Speed TP; Kavallaris M; Smyth GK; Scott HS
    BMC Genomics; 2008 Jul; 9():363. PubMed ID: 18671852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan.
    Yoshimi A; Toya T; Nannya Y; Takaoka K; Kirito K; Ito E; Nakajima H; Hayashi Y; Takahashi T; Moriya-Saito A; Suzuki K; Harada H; Komatsu N; Usuki K; Ichikawa M; Kurokawa M
    Ann Oncol; 2016 May; 27(5):887-95. PubMed ID: 26884589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Familial platelet disorder due to germline exonic deletions in
    Engvall M; Karlsson Y; Kuchinskaya E; Jörnegren Å; Mathot L; Pandzic T; Palle J; Ljungström V; Cavelier L; Hellström Lindberg E; Cammenga J; Baliakas P
    Leuk Lymphoma; 2022 Oct; 63(10):2311-2320. PubMed ID: 35533071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.
    Brown AL; Arts P; Carmichael CL; Babic M; Dobbins J; Chong CE; Schreiber AW; Feng J; Phillips K; Wang PPS; Ha T; Homan CC; King-Smith SL; Rawlings L; Vakulin C; Dubowsky A; Burdett J; Moore S; McKavanagh G; Henry D; Wells A; Mercorella B; Nicola M; Suttle J; Wilkins E; Li XC; Michaud J; Brautigan P; Cannon P; Altree M; Jaensch L; Fine M; Butcher C; D'Andrea RJ; Lewis ID; Hiwase DK; Papaemmanuil E; Horwitz MS; Natsoulis G; Rienhoff HY; Patton N; Mapp S; Susman R; Morgan S; Cooney J; Currie M; Popat U; Bochtler T; Izraeli S; Bradstock K; Godley LA; Krämer A; Fröhling S; Wei AH; Forsyth C; Mar Fan H; Poplawski NK; Hahn CN; Scott HS
    Blood Adv; 2020 Mar; 4(6):1131-1144. PubMed ID: 32208489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RUNX1, but not its familial platelet disorder mutants, synergistically activates PF4 gene expression in combination with ETS family proteins.
    Okada Y; Watanabe M; Nakai T; Kamikawa Y; Shimizu M; Fukuhara Y; Yonekura M; Matsuura E; Hoshika Y; Nagai R; Aird WC; Doi T
    J Thromb Haemost; 2013 Sep; 11(9):1742-50. PubMed ID: 23848403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies.
    Buijs A; Poddighe P; van Wijk R; van Solinge W; Borst E; Verdonck L; Hagenbeek A; Pearson P; Lokhorst H
    Blood; 2001 Nov; 98(9):2856-8. PubMed ID: 11675361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
    Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
    Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.
    Song WJ; Sullivan MG; Legare RD; Hutchings S; Tan X; Kufrin D; Ratajczak J; Resende IC; Haworth C; Hock R; Loh M; Felix C; Roy DC; Busque L; Kurnit D; Willman C; Gewirtz AM; Speck NA; Bushweller JH; Li FP; Gardiner K; Poncz M; Maris JM; Gilliland DG
    Nat Genet; 1999 Oct; 23(2):166-75. PubMed ID: 10508512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.